论文信息 - A phase II study of temozolomide therapy for poor-risk patients aged ⩾60 years with acute myeloid leukemia: low levels of MGMT predict for response - 字舞流文

A phase II study of temozolomide therapy for poor-risk patients aged ⩾60 years with acute myeloid leukemia: low levels of MGMT predict for response

M. Minden | R. Wells | S. Alibhai | A. Schimmer | J. Brandwein | A. Schuh | V. Gupta | W. Xu | L. Yang